— Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter 2019 adjusted earnings of $8.34 per share versus $8.02 per share expected.
— Total revenues increased by 4% to $3.67 billion versus $3.54 billion expected.
— Total product revenues rose by 4% driven by growth in multiple sclerosis drugs, spinal muscular atrophy drug Spinraza, biosimilars Benepali, Imraldi, and Flixabi.
— Research and development expense rose by 13% due to the inclusion of charges related to Samsung Bioepis transaction, related to the option exercise with Ionis Pharmaceuticals, and related to collaboration agreements with CAMP24 Therapeutics and Catalyst Biosciences.
— Looking ahead into the full year 2020, the company expects revenue in the range of $14-14.3 billion and adjusted earnings in the range of $31.50-33.50 per share. Analysts expect EPS of $33.03 on revenue of $14.06 billion.
— The earnings are anticipated to be in the range of $29.50-31.50 per share for the full year.
Most Popular
DRI Earnings: Darden Restaurants’ Q2 2026 sales and profit rise YoY
Darden Restaurants, Inc. (NYSE: DRI), a leading fine dining restaurant chain, on Thursday reported an increase in sales and adjusted earnings for the second quarter of fiscal 2026. Total sales
CarMax (KMX) Q3 2026 earnings drop on lower sales; results beat estimates
Used car retailer CarMax, Inc. (NYSE: KMX) on Thursday reported a decline in earnings for the third quarter of fiscal 2026, hurt by lower sales. However, both revenues and earnings
ACN Earnings: Key quarterly highlights from Accenture’s Q1 2026 financial results
Accenture (NYSE: ACN) reported its first quarter 2026 earnings results today. Revenues of $18.7 billion increased 6% in US dollars and 5% in local currency compared to the same period a
